143268-79-5

Basic information

• Product Name: 8-FLUORO-3,4-DIHYDRO-1H QUINOLIN-2-ONE
• Synonyms: 8-FLUORO-3,4-DIHYDRO-1H QUINOLIN-2-ONE;8-Fluoro-3,4-dihydroquinolin-2(1H)-one;8-Fluoro-3,4-dihydroquinolin-2(1H)
• CAS NO: 143268-79-5
• Molecular Formula: C9H8FNO
• Molecular Weight: 165.1643232
• Mol File: 143268-79-5.mol

Chemical Properties

• Boiling Point: 315.138 °C at 760 mmHg
• Flash Point: 144.39 °C
• Appearance: /
• Density: 1.242 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 8-FLUORO-3,4-DIHYDRO-1H QUINOLIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 8-FLUORO-3,4-DIHYDRO-1H QUINOLIN-2-ONE(143268-79-5)
• EPA Substance Registry System: 8-FLUORO-3,4-DIHYDRO-1H QUINOLIN-2-ONE(143268-79-5)

Safety Data

• Hazardous Substances Data: 143268-79-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
8-Fluoro-3,4-dihydro-1H quinolin-2-one is used as a research compound for exploring its potential biological activity. Its unique structure may contribute to various pharmacological effects, making it a candidate for drug development in the pharmaceutical industry.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 8-Fluoro-3,4-dihydro-1H quinolin-2-one is utilized as a starting material or intermediate in the synthesis of more complex molecules with therapeutic potential. Its structural features can be further modified to optimize its pharmacological properties and selectivity.
Used in Drug Discovery:
8-Fluoro-3,4-dihydro-1H quinolin-2-one serves as a potential lead compound in drug discovery processes. Its structural attributes may be leveraged to identify new therapeutic agents with improved efficacy and safety profiles for the treatment of various diseases and conditions.
Used in Chemical Synthesis:
In the chemical synthesis industry, 8-Fluoro-3,4-dihydro-1H quinolin-2-one can be employed as a building block or reactant in the preparation of other fluorinated quinoline derivatives. These derivatives may have diverse applications in various fields, including materials science, agrochemicals, and specialty chemicals.

Upstream product

• 348-54-9 2-Fluoroaniline 
• 349097-66-1 3-chloro-N-(2-fluoro-phenyl)-propionamide 

Downstream Products

• 1404367-02-7 9-fluoro-1-methyl-7-(5-phenyl-pyridin-3-yl)-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinoline 

Relevant articles and documents

Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a ]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability

CYP11B2 inhibition is a promising treatment for diseases caused by excessive aldosterone. To improve the metabolic stability in human liver miscrosomes of previously reported CYP11B2 inhibitors, modifications were performed via a combination of ligand-and

DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12/

NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, R7, R8, R9, R10, R11, R12/

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS

The present invention relates to novel M1 agonistic compounds of formula (I) and their use in the treatment of cognitive impairment associated i.a. with schizophrenia and in the treatment of other diseases mediated by the muscarinic M1 receptor.

QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY

The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.